Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source
Ashkan Shoamanesh,Robert G. Hart,Stuart J. Connolly,Scott E. Kasner,Eric E. Smith,Joan Martí-Fàbregas,Yan Yun Liu,Shinichiro Uchiyama,Robert Mikulik,Roland Veltkamp,Martin J. O’Donnell,George Ntaios,Keith W. Muir,Thalia S. Field,Gustavo C. Santo,Veronica Olavarria,Hardi Mundl,Helmi Lutsep,Scott D. Berkowitz,Mukul Sharma
DOI: https://doi.org/10.1001/jamaneurol.2020.3836
IF: 29.907
2021-01-01
JAMA Neurology
Abstract:<span><strong>Question</strong> <span>Does the presence of cerebral microbleeds (CMBs) modify the effect of rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily in patients with embolic stroke of undetermined source (ESUS)?</span><strong>Findings</strong> <span>In this analysis of a randomized clinical trial that included 3699 patients with ESUS, those with CMBs had higher rates of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality during 11 months of follow-up. There was, however, no treatment effect modification observed with CMBs for these outcomes.</span><strong>Meaning</strong> <span>In this study, CMBs marked an increased risk of adverse clinical outcomes in ESUS but did not appear to influence the effects of rivaroxaban.</span><strong>Importance</strong> <span>The reported associations of cerebral microbleeds with recurrent stroke and intracerebral hemorrhage have raised concerns regarding antithrombotic treatment in patients with a history of stroke and microbleeds on magnetic resonance imaging.</span><strong>Objective</strong> <span>To characterize microbleeds in embolic strokes of undetermined source (ESUS) and report interactions between microbleeds and the effects of random assignment to anticoagulant vs antiplatelet therapy.</span><strong>Design, Setting, and Participants</strong> <span>Subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) international, double-blind, randomized, event-driven phase 3 clinical trial. Participants were enrolled between December 2014 and September 2017 and followed up for a median of 11 months. The study setting included 459 stroke recruitment centers in 31 countries. Patients aged 50 years or older who had neuroimaging-confirmed ESUS between 7 days and 6 months before screening were eligible. Of these 7213 NAVIGATE ESUS participants, 3699 (51%) had information on cerebral microbleeds reported on their baseline clinical magnetic resonance imaging and were eligible for these analyses. Patients with a prior history of symptomatic intracerebral hemorrhage were excluded from the NAVIGATE ESUS trial.</span><strong>Interventions</strong> <span>Rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily.</span><strong>Main Outcomes and Measures</strong> <span>The primary outcome was recurrent stroke. Secondary outcomes were ischemic stroke, intracerebral hemorrhage, and all-cause mortality.</span><strong>Results</strong> <span>Microbleeds were present in 395 of 3699 participants (11%). Of patients with cerebral microbleeds, mean (SD) age was 69.5 (9.4) years, 241 were men (61%), and 201 were White (51%). Advancing age (odds ratio [OR] per year, 1.03; 95% CI, 1.01-1.04), East Asian race/ethnicity (OR, 1.57; 95% CI, 1.04-2.37), hypertension (OR, 2.20; 95% CI, 1.54-3.15), multiterritorial infarcts (OR, 1.95; 95% CI, 1.42-2.67), chronic infarcts (OR, 1.78; 95% CI, 1.42-2.23), and occult intracerebral hemorrhage (OR, 5.23; 95% CI, 2.76-9.90) were independently associated with microbleeds. The presence of microbleeds was associated with a 1.5-fold increased risk of recurrent stroke (hazard ratio [HR], 1.5; 95% CI, 1.0-2.3), a 4-fold risk of intracerebral hemorrhage (HR, 4.2; 95% CI, 1.3-13.9), a 2-fold risk of all-cause mortality (HR, 2.1; 95% CI, 1.1-4.3), and strictly lobar microbleeds with an approximately 2.5-fold risk of ischemic stroke (HR, 2.3; 95% CI, 1.3-4.3). There were no interactions between microbleeds and treatment assignments for recurrent stroke, ischemic stroke, or all-cause mortality. The HR of intracerebral hemorrhage on rivaroxaban was similar between persons with microbleeds (HR, 3.1; 95% CI, 0.3-30.0) and persons without microbleeds (HR, 3.0; 95% CI, 0.6-14.7; interaction <i>P</i> = .97).</span><strong>Conclusions and Relevance</strong> <span>Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes.</span><strong>Trial Registration</strong> <span><a href="https://clinicaltrials.gov/ct2/show/NCT02313909">ClinicalTrials.gov Identifier: NCT02313909</a></span></span>
clinical neurology